Wave Life Sciences Ltd.
WVE evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $941.9M
What it means
What to watch
Prepared research question
What matters most for WVE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · WVE
Wave Life Sciences Ltd. (WVE) is a clinical-stage biotechnology company leveraging its PRISM RNA medicines platform to develop therapies for rare and common disorders, with a focus on RNA editing and antisense oligonucleotides.
Key risk: No approved products
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$941.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 7 clinical trials for Wave Life Sciences Ltd..
Wave Life Sciences Ltd. (WVE) is a clinical-stage biotechnology company leveraging its PRISM RNA medicines platform to develop therapies for rare and common disorders, with a focus on RNA editing and antisense oligonucleotides.
- Cash & equivalents of $368.0M as of 2026-06-30 [sec].
- Total revenue of $2.3M and net income of -$69.4M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $453.5M as of 2026-06-30 [sec].
- Advanced WVE-006 (RNA editing) for AATD to a planned registrational trial with FDA alignment on a two-year study and one-year interim analysis for potential accelerated approval [news · published 2026-10-01].
- Reported positive 48-week FORWARD-53 data for WVE-N531 in Duchenne muscular dystrophy, showing consistent dystrophin expression and best-in-class muscle delivery, with NDA filing activities underway for 2026 [sec · filed 2026-04-30].
What works
- Strong cash position of $368.0M as of 2026-06-30 provides runway into 2028 [sec] [news · published 2026-05-20].
- FDA alignment on a registrational pathway for WVE-006 (RNA editing) in AATD, including potential accelerated approval based on biomarkers [news · published 2026-10-01].
- Positive clinical data for WVE-N531 in DMD with consistent dystrophin expression and multiple indicators of improved muscle health [sec · filed 2026-04-30].
- Strategic collaboration with GSK, including proof-of-mechanism milestone for WVE-006 and advancement of multiple programs [sec · filed 2026-04-30].
What to weigh
- Net loss of $69.4M for the period ending 2026-06-30, reflecting significant ongoing R&D expenses [sec].
- Total revenue of only $2.3M as of 2026-06-30, indicating no approved products generating substantial sales [sec].
- Mixed clinical trial data have led to a 'hold' rating from some analysts, despite a strong cash runway [news · published 2026-05-07].
- WVE-003 in Huntington's disease reported a serious adverse event (SAE) post-final safety visit, though assessed as not related to the drug [sec_mda · as of 2026-07-30].
From the filings
Quoted directly from source documents.
FDA alignment on registrational trial for WVE-006
“Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers”
News · October 1, 2026
GSK collaboration milestone
“Achieved proof of mechanism milestone for WVE-006”
SEC filings · April 30, 2026
Catalyst timeline
- 2021-09-06 · Phase 2 start for WVE-003 in Huntington's disease (SELECT-HD) — A randomized, double-blind, placebo-controlled Phase 1b/2a study of WVE-003 administered intrathecally in patients with Huntington's disease.
- 2021-09-28 · Phase 2 start for WVE-N531 in Duchenne muscular dystrophy — An open-label Phase 1b/2 study of WVE-N531 in patients with Duchenne muscular dystrophy.
- 2022-12-14 · Phase 2 start for WVE-004 in ALS/FTD — A multicenter, open-label extension study to evaluate safety, pharmacodynamics, and clinical effects of WVE-004 in patients with C9orf72-associated ALS and/or FTD.
- 2023-11-14 · Phase 1 start for single ascending dose study — A Phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, and pharmacokinetic study of single ascending doses.
Risks & what to watch (3)›
Key risks
- No approved products — Wave has no marketed products; revenue is minimal ($2.3M as of 2026-06-30) and depends on partnerships and milestones [sec].
- Clinical trial execution risk — WVE-003 in HD had a reported SAE (though assessed as unrelated), and mixed trial data have been noted [sec_mda · as of 2026-07-30] [news · published 2026-05-07].
- Regulatory uncertainty — While FDA aligned on WVE-006 pathway, accelerated approval depends on biomarker data from a two-year trial with interim analysis [news · published 2026-10-01].
What to watch
- Initiation and interim results of the two-year registrational trial for WVE-006 in AATD, with potential accelerated approval decision after one year [news · published 2026-10-01].
- NDA filing for WVE-N531 in Duchenne muscular dystrophy planned for 2026, and FDA feedback on the submission [sec · filed 2026-04-30].
- Progress of WVE-003 in Huntington's disease, including FDA discussions on accelerated approval using caudate atrophy as an endpoint [sec_mda · as of 2026-07-30].
- Cash runway into 2028 and any additional financing or partnership milestones that may extend or alter the financial outlook [news · published 2026-05-20].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Wave Life Sciences Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Wave Life Sciences Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.23 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 10.8%
- Days to cover
- 3.9
- Shares short
- 16,720,976
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
WVE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Wave Life Sciences Ltd.?
Wave Life Sciences Ltd. (WVE) is a clinical-stage biotechnology company leveraging its PRISM RNA medicines platform to develop therapies for rare and common disorders, with a focus on RNA editing and antisense oligonucleotides.
Who is the CEO of Wave Life Sciences Ltd.?
Dr. Paul B. Bolno M.B.A., M.D. is the chief executive officer of Wave Life Sciences Ltd. (WVE).
Where is Wave Life Sciences Ltd. headquartered?
Wave Life Sciences Ltd. (WVE) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Wave Life Sciences Ltd. focus on?
Wave Life Sciences Ltd. develops therapies across Oncology, Rare Disease, Neurology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.